Press Releases

Date Title and Summary Additional Formats
Toggle Summary Innoviva Reports Second Quarter 2021 Financial Results
Royalties increased by 44% to $104.3 million in the second quarter of 2021, compared to the same quarter in 2020. Repurchased GSK’s full 32% equity stake in Innoviva for $392 million purchase price. Strategically invested an additional $20 million into Entasis Therapeutics Holdings Inc.
View HTML
Toggle Summary Innoviva Announces Strategic Repurchase of GSK’s Equity Stake
Innoviva to repurchase GSK’s current 32% stake in the company for $392 million BURLINGAME, Calif. --(BUSINESS WIRE)--May 20, 2021-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today announced the execution of definitive agreement to purchase of GSK’s equity stake in Innoviva ,
View HTML
Toggle Summary Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that it has completed the initial closing of an approximately $7.5
View HTML
Toggle Summary Innoviva Reports First Quarter 2021 Financial Results
Royalties increased by 8% to $89.0 million in the first quarter of 2021, compared to the same quarter in 2020. Invested an additional $20.0 million into Armata Pharmaceuticals Inc. (NYSE:ARMP), an anti-infectives leader, in the first quarter of 2021. Deborah L.
View HTML
Toggle Summary Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva
MARINA DEL REY, Calif. , March 17, 2021 /PRNewswire/ --  Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today
View HTML
Toggle Summary Innoviva Reports Fourth Quarter 2020 Financial Results
Royalties increased by 18% to $93.9 million in the fourth quarter of 2020, compared to the same quarter in 2019. Invested $300 million into a fund advised by Sarissa Capital Management LP as a part of a strategic partnership designed to enhance returns on our capital and accelerate execution of our
View HTML
Toggle Summary Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs
MARINA DEL REY, Calif. , Jan. 27, 2021 /PRNewswire/ --  Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today
View HTML
Toggle Summary Innoviva Reports Third Quarter 2020 Financial Results
Royalties increased by 33% to $92.2 million in the third quarter of 2020, compared to the same quarter in 2019. Invested an additional $12.5 million into the common stock and warrants of Entasis Therapeutics Holding Inc. (NASDAQ: ETTX), a leader in anti-infectives development. BURLINGAME, Calif.
View HTML
Toggle Summary FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US
New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm LONDON & BURLINGAME, Calif. --(BUSINESS WIRE)--Sep. 9, 2020-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration
View HTML
Toggle Summary Innoviva Reports Second Quarter 2020 Financial Results
Royalties increased by 7% to $72.4 million in the second quarter of 2020, compared to the same quarter in 2019. Pavel Raifeld named as Chief Executive Officer. Invested $35 million into common stock and warrants of Entasis Therapeutics Holding Inc. (NASDAQ: ETTX), a leader in anti-infectives
View HTML

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Contact

Toll-Free
877-202-1097

Innoviva Investor Relations & Media
Sloane and Company
212-486-9500

For business development inquiries,
please contact investor.relations@inva.com.